Looking to buy a new Kindle? We've tested all of Amazon's ereaders and are here to help you find the best one for you.

The Oxford study based on the health records of 200,000 people from the US, found a 17 per cent reduction in dementia diagnoses in the six years following immunisation with a recombinant vaccine ...

GSK managed to beat analysts’ revenue predictions for the first quarter of the year, despite an 8% decline in turnover pegged back by declines in COVID-19-related products. The group posted £6. ...

Now, Americans 50 and older are urged to get the newer, more effective vaccine, Shingrix. “It’s a very robust finding,” said Dr. Pascal Geldsetzer of Stanford University, the study’s lead researcher.

At the time, people received a first-generation vaccine called Zostavax.An important next step is testing whether today's vaccine, Shingrix, also offers dementia protection, Nagel said.

Last year, Oxford researchers reported an even stronger protective effect in people who received Shingrix, a newer type of vaccine. Dr Sheona Scales, director of research at Alzheimer’s Research UK, ...

It’s now been replaced by Shingrix, a genetically engineered version of the vaccine that contains only certain proteins from the virus. Shingrix is more effective against varicella-zoster – 97 ...

An important next step is testing whether today’s vaccine, Shingrix, also offers dementia protection, Nagel said. Another research group recently reported some evidence that it does. Vaccine ...

It’s now been replaced by Shingrix, a genetically engineered version of the vaccine that contains only certain proteins from the virus. Shingrix is more effective against varicella-zoster – 97% versus ...